The United Kingdom and the United States have reached a major bilateral deal that will keep no duties on British drug exports going into the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has committed to boost spending on drugs through the NHS. This move secures that import taxes on these vital exports will stay at nothing for a period of three years.
This development is in response to previous threats to significantly raise import taxes on branded pharmaceutical imports, with figures floated as high as double the cost.
"This agreement with the Britain strengthens the worldwide climate for cutting-edge drugs and introduces long-overdue equity to American-British pharmaceutical trade," a release declared.
Commercial Significance
Drugs constitute one of the UK's largest goods shipped to the America, which is by far the primary destination for large companies like GSK and AstraZeneca.
Statistics reveal that in the one-year period prior to last September, the UK sold drugs worth over eleven billion pounds to the US. This value made up 17.4% of total UK exports in that span.
"This agreement protects work, stimulates funding and sets the stage for the UK to establish itself as a worldwide center for life sciences," the Business and Trade Secretary remarked.
Key UK Commitments
The deal involves several notable commitments from the United Kingdom:
- Price Threshold Increase: The UK will increase the price threshold at which it considers new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a target to raise total NHS spending on treatments from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Payback Limit: The amount pharmaceutical firms must refund to the NHS to control costs will be limited at fifteen percent. Previously, repayments were more than twenty percent.
Recent Tensions
The deal takes place against a ongoing row between the sector and the British authorities over spending levels and regulatory access.
The disagreement were heightened by arguments that US patients were paying a premium for the equivalent treatments than patients in the UK and Europe.
In recent months, several significant pharmaceutical investments in the UK have been delayed or scrapped, while substantial funding commitments have been announced toward projects in the United States.
The Science Minister stated that the NHS had to spend more on drugs, noting that its expenditure on drugs had shrunk as a percentage of its overall budget over the last ten years.
